GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » EV-to-EBITDA

NewAmsterdam Pharma Co NV (FRA:KH6) EV-to-EBITDA : -7.63 (As of May. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NewAmsterdam Pharma Co NV's enterprise value is €1,241.90 Mil. NewAmsterdam Pharma Co NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-162.67 Mil. Therefore, NewAmsterdam Pharma Co NV's EV-to-EBITDA for today is -7.63.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's EV-to-EBITDA or its related term are showing as below:

FRA:KH6' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.06   Med: 10.18   Max: 15.24
Current: -7.56

During the past 4 years, the highest EV-to-EBITDA of NewAmsterdam Pharma Co NV was 15.24. The lowest was -9.06. And the median was 10.18.

FRA:KH6's EV-to-EBITDA is ranked worse than
100% of 463 companies
in the Biotechnology industry
Industry Median: 9.32 vs FRA:KH6: -7.56

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), NewAmsterdam Pharma Co NV's stock price is €17.80. NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.978. Therefore, NewAmsterdam Pharma Co NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


NewAmsterdam Pharma Co NV EV-to-EBITDA Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EV-to-EBITDA Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -18.86 -3.28

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - -18.86 - -3.28

Competitive Comparison of NewAmsterdam Pharma Co NV's EV-to-EBITDA

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-EBITDA falls into.



NewAmsterdam Pharma Co NV EV-to-EBITDA Calculation

NewAmsterdam Pharma Co NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1241.896/-162.671
=-7.63

NewAmsterdam Pharma Co NV's current Enterprise Value is €1,241.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-162.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NewAmsterdam Pharma Co NV  (FRA:KH6) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NewAmsterdam Pharma Co NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=17.80/-1.978
=At Loss

NewAmsterdam Pharma Co NV's share price for today is €17.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.978.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


NewAmsterdam Pharma Co NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines